Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1632 1638 1656
This examiner grants 42% of resolved cases
Michael C Wilson, working in Art Unit 1632 within Tech Center 1600, has overseen 938 resolved cases. The allowance rate of 41.5 percent indicates the outcomes for applications in this unit. This rate is paired with a median days to allowance of 1349, reflecting the duration for successful prosecution.
The data highlights an interview lift of 17.9 percent, which suggests that personal interaction can be a strategy for addressing rejections. Given the 41.5 percent allowance rate, practitioners might consider interviews to discuss the application. The 938 resolved cases provide a dataset for evaluating these trends.
In Tech Center 1600, the 1349 median days to allowance suggests the time required for a grant. The 17.9 percent interview lift provides a tactical option for those seeking to change their chances relative to the baseline allowance rate. These figures define the landscape for applications assigned to Art Unit 1632.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17321645 | HIGHLY PARALLEL ASSAYS FOR SIMULTANEOUS IDENTIFICATION OF ANTIBODY SEQUENCES AND BINDING PARTNERS | Final Rejection | THE UNIVERSITY OF BRITISH COLUMBIA |
| 18437160 | GENETICALLY MODIFIED MSC AND THERAPEUTIC METHODS | Final Rejection | The Regents of the University of California |
| 17351113 | METHODS FOR THE TREATMENT OF DANON DISEASE AND OTHER DISORDERS OF AUTOPHAGY | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17640585 | DEVELOPMENT OF EMBRYONIC-LIKE TISSUE FROM STEM CELLS | Final Rejection | The Regents of the University of Michigan |
| 18838519 | Cerebrovascular-Tumor-On-A-Chip | Non-Final OA | Ohio State Innovation Foundation |
| 18899268 | Multiplexed Genome Editing | Non-Final OA | President and Fellows of Harvard College |
| 16624081 | A METHOD OF TREATING EPIDERMOLYSIS BULLOSA USING MUSE CELLS | Final Rejection | TOHOKU UNIVERSITY |
| 18734482 | LOW AFFINITY FcyR DEFICIENT MICE | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18543857 | HUMAN LAMBDA LIGHT CHAIN MICE | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17113485 | GENETICALLY MODIFIED MICE THAT EXPRESS HUMANIZED IgG1 LACKING A CH1 DOMAIN AND HUMANIZED UNIVERSAL LIGHT CHAIN | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 17041252 | GENETICALLY MODIFIED NON-HUMAN ANIMALS FOR GENERATING THERAPEUTIC ANTIBODIES AGAINST PEPTIDE-MHC COMPLEXES, METHODS OF MAKING AND USES THEREOF | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17910992 | NK CELLS AND USES THEREOF FOR TREATMENT OF MICROBIAL INFECTIONS | Final Rejection | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL |
| 18305342 | Novel Animal Model for Autoimmune Disease | Non-Final OA | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY |
| 18132164 | COMPOSITIONS, METHODS AND USES FOR IN VITRO AND IN VIVO GENERATION OF FUNCTIONAL THYMIC TISSUE | Final Rejection | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE |
| 18033442 | MOUSE MODEL FOR BIO-IMAGING OF INFLAMMATORY SIGNALS, PREPARATION METHOD THEREFOR AND USE THEREOF | Final Rejection | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION |
| 18489274 | MODIFIED MAMMALIAN CELLS | Non-Final OA | Hoffmann-La Roche Inc. |
| 18737201 | SELF-INACTIVATING LENTIVIRAL VECTOR ENCODING BETA- OR GAMMA-GLOBIN | Non-Final OA | Children's Hospital Medical Center |
| 18727953 | COMPOSITIONS USEFUL IN TREATMENT OF METACHROMATIC LEUKODYSTROPHY | Non-Final OA | The Trustees of the University of Pennsylvania |
| 18197151 | GENETICALLY EDITED ALBINO-RED GERMLINES OF TILAPIA FISH | Non-Final OA | The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization |
| 17264752 | GENE THERAPY METHODS TO CONTROL ORGAN FUNCTION | Non-Final OA | Cornell University |
| 16477110 | Methods of Treating Brain Injury Using Cord Blood or a Component Thereof | Final Rejection | Duke University |
| 18710764 | CELL PRODUCTION METHOD | Non-Final OA | Takeda Pharmaceutical Company Limited |
| 18647191 | METHOD FOR PRODUCING VASCULARIZED RESPIRATORY ORGANOID FUSED WITH BLOOD VESSEL ORGANOID | Non-Final OA | THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 18165038 | A METHOD FOR CONSTRUCTING A COFILIN-1 TRANSGENIC MODEL AND USE THEREOF | Non-Final OA | National Yang Ming Chiao Tung University |
| 18609867 | TRANSGENIC MOUSE EXPRESSING HUMAN CEREBLON | Non-Final OA | CELGENE CORPORATION |
| 17728927 | THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/Cas SYSTEMS | Final Rejection | The Children's Medical Center Corporation |
| 17825784 | TOOLS AND METHODS FOR USING CELL DIVISION LOCI TO CONTROL PROLIFERATION OF CELLS | Non-Final OA | Sinai Health System |
| 17625063 | HLA-H IN MEDICINE AND DIAGNOSTICS | Final Rejection | Intellexon GmbH |
| 17632376 | DONOR PIGS FOR XENOTRANSPLANTATION | Final Rejection | NZENO LIMITED |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy